

## Plain English Summary

# Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer

## What does the guidance say?

Dacomitinib (Vizimpro) is recommended for listing on the Standard Drug List (SDL) for government subsidy for locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.

## What is non-small-cell lung cancer (NSCLC)?

Lung cancer occurs when abnormal cells grow uncontrollably in one or both of the lungs. Non-small-cell lung cancer is the most common type of lung cancer. Doctors classify NSCLC into different subtypes depending on the type of cells in the lung that are affected. Common symptoms of lung cancer include coughing, chest pain and trouble breathing.

When the cancer spreads to both lungs or to other parts of the body, this is known as advanced or metastatic disease.

## What is an epidermal growth factor receptor (EGFR) mutation?

The EGFR gene helps cells grow and divide. Some patients with NSCLC have a mutation in the EGFR gene which causes abnormal cell growth. EGFR mutations are common in Asian populations.

Doctors test patients with lung cancer to see if they have an EGFR mutation so they can determine the appropriate type of treatment.

## What is dacomitinib?

Dacomitinib belongs to a group of medicines called tyrosine kinase inhibitors (TKIs) which can stop cells from growing and dividing and can prevent cancer from spreading.

It is taken orally each day. Your doctor will tell you how long you will need to take dacomitinib for.

## Plain English Summary

# Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer

## Who can have dacomitinib?

Adults with non-small-cell lung cancer can have dacomitinib if they have a mutation in the EGFR gene confirmed by a diagnostic test, and the cancer has spread to both lungs or to other organs.

Your doctor can advise if dacomitinib is a suitable treatment for you.

## Why was dacomitinib recommended for subsidy?

ACE evaluates how well a treatment works in relation to how much it costs compared to other treatments. Dacomitinib was recommended because its benefit in improving survival and quality of life for certain patients with advanced EGFR mutation-positive NSCLC justifies its cost compared to other tyrosine kinase inhibitors.

## What does listing on SDL mean for me?

Dacomitinib has been listed on the Standard Drug List (SDL). Drugs on SDL are subsidised at 50% for all Singaporean citizens who are treated in a public healthcare institution. Patients from lower to middle income households may receive a higher subsidy of up to 75%.

**Published: 27 July 2021**

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. It publishes guidances on diagnosing, treating, and preventing different medical conditions based on the latest research information available worldwide.

This summary is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition.

To find out more about ACE visit [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg)